


Sarcosine Analyzed with LCMS - AppNote

Separation of Potential Urine Biomarker from Isobaric &-Alanine

This developed LCMS method can separate Sarcosine from Beta-Alanine in serum and urine samples without using labor intensive sample derivatization. Since Sarcosine is considered a potential biomarker for prostate cancer risk and aggressiveness, it is essential to resolve and accurately quantify this compound in the presence of isobaric (same m/z) Beta-Alanine.

The developed method is Sensitive, Specific, Quantitative, and Reproducible (%RSD = 0.1). It can be used in large scale studies with numerous samples (high throughput of the method due to simple sample preparation).



Peaks:

- 1. Sarcosine
- 2. ß-Alanine

Method Conditions

Column: Cogent Diamond Hydride[™], 4μm, 100Å

Catalog No.: 70000-15P-2 **Dimensions:** 2.1 x 15mm

Mobile Phase:

A: 50% Isopropyl Alcohol / 50% DI Water / 0.1% Acetic Acid

B: 97% Acetonitrile / 3% DI Water / 0.1% Acetic Acid



Gradient:

Time (minutes)	%B
0	75
3	75
4	65
5	65
10	20
12	75

Temperature: 50°C

Post Time: 5 minutes

Flow rate: 0.6mL / minute

Detection: ESI - POS - Agilent 6210 MSD TOF Mass Spectrometer

Injection vol.: 1µL

Sample Preparation: 10mg / L each of Sarcosine and Beta-Alanine in 50:50 A:B

Note: When Reversed Phase Columns were evaluated for their ability to separate Sarcosine from Beta-Alanine, both compounds eluted at the solvent front and were not separated. To achieve separation, a very intensive sample preparation has to be employed (e.g. derivatization) when using RP methods.



Attachment

No 129 Sarcosine Analyzed with LCMS pdf 0.2 Mb Download File

Printed from the Chrom Resource Center

MicroSolv Technology Corporation

9158 Industrial Blvd. NE, Leland, NC 28451 tel. (732) 380-8900, fax (910) 769-9435

Email: customers@mtc-usa.com

Website: www.mtc-usa.com

Date: 05-05-2024